Back Number
2023
- December 15 Top-line Results of Phase 3 Clinical Study of TO-208 for the Treatment of Molluscum Contagiosum in Japan（PDF）
- December 13 Signing of an Agreement for the Exclusive Development and Commercialization of GRAZAX®,an Allergen Immunotherapy (Sublingual Immunotherapy) Drug for Grass Pollinosis in Japan（PDF）
- November 8 Announcement regarding Transition to Company with Audit and Supervisory Committee,and Changes of Representative Director and Officers（PDF）
- October 31 " Financial Results " was updated.
- September 15 JT Files New Drug Application of JTE-061 Cream,Aryl hydrocarbon Receptor (AhR) agonist,for the Treatment of Atopic Dermatitis and Plaque Psoriasis in Japan（PDF）
- July 31 " Financial Results " was updated.
- June 16 " Annual Report " was updated.
- April 28 " Financial Results " was updated.
- March 16 Torii’s Views on Report from ISS, a Proxy Advisory Firm, On Proposals for Torii’s General Meeting of Shareholders（PDF）
- March 7 " NOTICE OF THE 131st ANNUAL GENERAL MEETING OF SHAREHOLDERS（PDF） " was updated.
- February 17 Notice of the Opinion of the Board of Directors Regarding the Shareholder Proposal（PDF）
- February 10 " Financial Results " was updated.
- February 10 Torii has announced Medium-Term Management Plan 2023-2025（PDF）
- January 26 Torii has entered into License Agreement with Nogra Pharma Limited to Develop & Commercialize NAC-GED-0507 in Japan（PDF）
2022
- October 31 " Financial Results " was updated.
- September 16 Positive Top-line Results of Phase 3 Clinical Study (Comparative Study) of JTE-061 (tapinarof) Cream, Aryl Hydrocarbon Receptor (AhR) Agonist, in Patients with Plaque Psoriasis in Japan（PDF）
- July 29 " Financial Results " was updated.
- July 20 Top-line Results of Phase 3 Clinical Study (Comparative Study) of JTE-061 (tapinarof) Cream, Aryl hydrocarbon Receptor (AhR) agonist, in Adult and Adolescent Patients with Atopic Dermatitis in Japan（PDF）
- June 16 " Annual Report " was updated.
- April 28 " Financial Results " was updated.
- March 14 Torii’s Views on Report from ISS, a Proxy Advisory Firm, On Proposals for Torii’s General Meeting of Shareholders（PDF）
- March 8 " NOTICE OF THE 130th ANNUAL GENERAL MEETING OF SHAREHOLDERS（PDF） " was updated.
- February 18 Notice of the Opinion of the Board of Directors Regarding the Shareholder Proposal（PDF）
- February 10 " Financial Results " was updated.
- February 10 Torii has announced New Corporate Philosophy, Medium-/Long-Term Business Vision, and Medium-Term Management Plan 2022-2024（PDF）
2021
- December 14 Top-line Results of Phase 3 Clinical Study of JTE-052 Ointment, JAK Inhibitor, in Infant Patients with Atopic Dermatitis in Japan（PDF）
- October 29 " Financial Results " was updated.
- July 30 " Financial Results " was updated.
- June 9 " Annual Report " was updated.
- May 26 Listing on the Japanese National Health Insurance Drug Price List and Launch of CORECTIM® Ointment 0.25% in Japan（PDF）
- April 28 " Financial Results " was updated.
- April 21 Listing on the Japanese National Health Insurance Drug Price List and Launch of ORLADEYO Capsules 150mg for Suppression of HAE Attacks in Japan（PDF）
- March 23 JT Receives Approvals of CORECTIM® Ointment 0.25% and CORECTIM® Ointment 0.5% for the Treatment of Pediatric Atopic Dermatitis in Japan（PDF）
- March 23 JT Receives Approval for Additional Indication for Iron Deficiency Anemia for Riona® and Promotion to Start in Japan（PDF）
- March 17 Torii has entered into License Agreement with Verrica Pharmaceuticals to Develop & Commercialize VP-102 in Japan（PDF）
- February 4 " Financial Results " was updated.
- January 22 OrphanPacific Inc.Receives Manufacturing and Marketing Approval of ORLADEYOCapsules150mg for Suppression of HAE Attacksin Japan（PDF）